SCHEMBL4863471

SCHEMBL4863471

OCC(CO)Nc1nc(NCc2ccccn2)c2c(-c3ccccc3)coc2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 3/20 0.50
CCNE1 P24864 2/20 0.50
MAPK1 P28482 2/20 0.50
CDK1 P06493 1/20 0.50
CDK4 P11802 1/20 0.50
CCNB1 P14635 1/20 0.50
CCND1 P24385 1/20 0.50
CDK7 P50613 1/20 0.50
CCNH P51946 1/20 0.50
KCNA5 P22460 12/20 0.47
KCNH2 Q12809 10/20 0.47
JAK2 O60674 2/20 0.47
TYK2 P29597 2/20 0.47
GSK3B P49841 2/20 0.47
JAK3 P52333 2/20 0.47
BTK Q06187 2/20 0.47
AURKB Q96GD4 2/20 0.47
IRAK4 Q9NWZ3 2/20 0.47
IGF1R P08069 1/20 0.47
PIM1 P11309 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4867404 0.80 KCNH2 (0.47) CDK2CCNE1MAPK1KCNA5KCNH2
SCHEMBL2368704 0.80 MAPK1 (0.64) CDK2CCNE1MAPK1CDK1CDK4
SCHEMBL4860362 0.79 KCNH2 (0.51) CDK2CCNE1MAPK1KCNA5KCNH2
SCHEMBL4869478 0.78 TNF (0.61) CDK2CCNE1MAPK1KCNA5KCNH2
SCHEMBL4865901 0.78 KCNH2 (0.49) CDK2CCNE1MAPK1KCNA5KCNH2
SCHEMBL4864910 0.76 PIK3CA (0.52) CDK2CCNE1KCNA5KCNH2JAK2
SCHEMBL4862847 0.76 KCNA5 (0.48) CDK2CCNE1MAPK1KCNA5KCNH2
SCHEMBL5242498 0.76 KCNH2 (0.43) CDK2CCNE1MAPK1KCNA5KCNH2
SCHEMBL4867940 0.72 KCNA5 (0.47) CDK2CCNE1KCNA5KCNH2JAK2
SCHEMBL4869591 0.70 KCNA5 (0.52) CDK2MAPK1KCNA5KCNH2JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456187-B2 Furanopyrimidine compounds as potassium ion channel inhibitors XENTION LIMITED (GB) 2008-11-25 US claimed
EP-1758909-A1 FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS Xention Limited (GB) 2007-03-07 EP claimed
WO-2005121149-A1 FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2005-12-22 WO claimed
US-20050282829-A1 Furanopyrimidine compounds as potassium ion channel inhibitors XENTION DISCOVERY LTD. (GB) 2005-12-22 US claimed
US-7456187-B2 Furanopyrimidine compounds as potassium ion channel inhibitors XENTION LIMITED (GB) 2008-11-25 US disclosed
EP-1758909-A1 FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS Xention Limited (GB) 2007-03-07 EP disclosed
WO-2005121149-A1 FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2005-12-22 WO disclosed
US-20050282829-A1 Furanopyrimidine compounds as potassium ion channel inhibitors XENTION DISCOVERY LTD. (GB) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282829-A1 Furanopyrimidine compounds as potassium ion channel inhibitors KCNH3, HCN4, KCNH2 CDK2 2322/4885CCNE1 2733/4885MAPK1 1946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.